Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23-24
Global Session on Small Nucleic Acid Drug Innovation
Stay tuned
Meeting Planner
Zicai Liang:Chairman and CEO, Ribo Life Science
Yan Chang:Chairman and President, InnoStar
Howe Li:Chairman, Livius Biotech
July 23
09:00-09:30 The Third Wave of Modern Pharmaceuticals – From the Prosperity of Hepatic Delivery to the Surging Advance of Extrahepatic Delivery in Small Nucleic Acid Pharmaceuticals
Zicai Liang:Chairman and CEO, Ribo Life Science
09:30-09:50 Differentiated Project Initiation and Pipeline Layout Strategies for Small Nucleic Acid Drugs Based on Disease Mechanisms
Dong Xie:Chairman 、CEO 、CSO, Frontier Biotechnologies Inc.
09:50-10:10 Applications and Progress of siRNA Drugs in the Field of Lipid Management
Lianshan Zhang:Director & Executive Vice President, Hengrui Medicine
10:10-10:30 Dual-Target Oligonucleotides Enable Novel Therapeutic Strategies for Comorbid Metabolic Disorders
Xinjian Liu:CSO & Vice President, BeBetter Med Inc.
10:30-11:00 Break
11:00-11:15 Development of antisense oligonucleotides for HBV cure
Chris Yang:Co-founder & CSO, AusperBio
11:15-12:00 Roundtable Discussion: The Next Five Years of the Small Nucleic Acid Drug Industry
Quan Gan (Moderator):Managing Director, SDIC Investment
Zicai Liang:Chairman and CEO, Ribo Life Science
Dong Xie:Chairman, CEO & CSO, Frontier Biotechnologies Inc.
Dongxu Shu:Founder, Chairman & CEO, Argo Biopharma
Xin Xie:Executive Director & Senior Vice President, Sino Biopharmaceutical
Nannan Chang:Managing Director, GL Ventures
12:00-13:00 Lunch
13:00-13:15 Developing a New Generation of siRNA Drugs Centered on AI
Xiangrui Gao:Head of Nucleic Acid Drug R&D, XtalPi
13:15-13:30 TBD
Qian Li:Chairman, Beijing Sun-novo Pharmaceutical Research
13:30-13:45 siRNA: Reshaping the Therapeutic Landscape of Chronic Diseases
Qunsheng Ji:CEO, Sirius Therapeutics
13:45-14:00 siRNA vs ASO: Two Paths of Oligonucleotide Innovation for Chronic Hepatitis B
Qing Zhu:Senior Vice President,Brii Bio
14:00-14:15 Toxicological Evaluation of Small Nucleic Acid Drugs: Key Considerations and Case Analysis
Naping Tang:Vice President, InnoStar
14:15-14:30 How Anlong Biotech Stands Out in the Small Nucleic Acid Industry
Chunlin Zhao:Founder, AnlongBio; Founding Partner, Anlong Fund
14:30-14:45 Development and Application of Small Nucleic Acid Drugs in the Cardiovascular Field
Xiaoming Zou:CEO, Bisirna Therapeutics
14:45-15:00 Breakthrough in delivery platform advances the application of small nucleic acid drugs in chronic diseases
Lijuan Wang:CSO, Shenzhen Salubris Pharmaceuticals
15:00-15:20 Coffee Break
15:20-15:35 Extrahepatic Delivery and Clinical Research of Small Nucleic Acid Drugs
Yuanyu Huang:Founder & Chairman, Rigerna Therapeutics
15:35-15:50 Novel Cross-Modal Drug R&D Technologies Based on Small Nucleic Acids
Xingquan Ma:Co-President, ChemPartner
15:50-16:05 Early Clinical Trial Design and Safety Evaluation of Nucleic Acid Drugs
Ruihua Dong:Director of Clinical Research Ward, Beijing Friendship Hospital, Capital Medical University
16:05-16:20 Systematic Solutions for Small Nucleic Acids: From Lab-Scale Trials to Commercial Production
Yanhua Wang:Product Director, Small Nucleic Acid Solution Division, Tofflon
16:20-16:35 Neural Mouse Models: Bridging Preclinical Efficacy to Clinical Outcomes
Shuxin Xu:Deputy Director of Preclinical Service Platform, Head of Metabolism Pipeline & Chief Scientist of Metabolism, GemPharmatech
16:35-16:50 Antisense makes sense
Haisheng Wang:Founder & CEO, SicaGene
16:50-17:30 Roundtable Discussion: Technical Challenges and Breakthroughs of Small Nucleic Acid Drugs
Hao Li (Moderator):Chairman, Livius Biotech
Xiaobin Zhao:Founder, Chairman & General Manager, HaiChang Biotech
Xiaoye Su:Dean of Research Institute, CSPC Pharmaceutical Group
Haizhou Zhang:Senior Vice President, GeneScience Pharmaceuticals (Changchun)
Yun Zhu:General Manager, YUN HO BIO
Hu Xiaomin:Former Senior Pharmacist/Senior Reviewer at CDE (Center for Drug Evaluation)
July 24
09:00-09:15 MicroRNA (miRNA) Therapies for Aging-Related Diseases
Hao Li:Chairman, Livius Biotech
09:15-09:30 Beyond the Liver: SCAD and LiCO—Clinically Validated Extrahepatic Delivery Platforms for Oligonucleotide Therapeutics
Longcheng Li:Founder, Chairman & CEO, Ractigen Therapeutics
09:30-09:45 Innovative siRNA Therapeutics for Pulmonary Diseases
Yi Huang:General Manager, Innovative Drug Division, Gowell Pharmaceutical
09:45-10:00 Introduction to Sirnaomics’ GalAhead Delivery Platform and Clinical Progress of STP122G
Weiwei Tian:VP, Sirnaomics
10:00-10:15 Overview of Youcare Pharmaceutical’s Oligonucleotide Innovation Platform and R&D Pipeline
Gengshen Song:Director, Deputy General Manager & Dean of Pharmaceutical Research Institute, Youcare Pharmaceutical Group Co.,Ltd.
10:15-10:30 AI-Driven Targeted RNA Therapeutics Platform
Rong Xin:CEO, RecoRNA
10:30-10:50 Break
10:50-11:05 Conjugation Empowerment: Delivery Advancements & Multi-Target Hurdles for Next-Generation siRNA Drugs
Chengjiang Zhao:Co-Founder, Youjia Biotech
11:05-11:20 From bench to bed –case study of siRNA drugs for metabolism/CVD
Jinqiao Wan:Chairman CEO ,Leaderna
11:20-12:00 Roundtable Discussion: Innovation of Small Nucleic Acid Drugs from the Investor's Perspective
Fei Qi (Moderator):Executive Director, Legend Capital
Zhiping Cui:General Manager, New Drug Fund, Fosun Health Capital; Chairman, Hepa Thera
Li Wang:Member of Investment Banking Committee & Head of Healthcare Department, Guotai Haitong Securities
Junhong Li:Partner, Lapam Capital
Wei Ding:Partner, Apricot Capital
12:00-13:00 Lunch
13:00-13:15 Extrahepatic Targeted Delivery Technologies Based on lncRNA
Xu Song:Founder, lncTAC
13:15-13:30 Oligonucleotide Drug Development: Translational Barriers and Clinical Countermeasures in First-in-Human Trials and Proof-of-Concept Studies
Junlong Wang:General Manager, InnoClinic
13:30-13:45 Small Nucleic Acids, Grand Era — Global Industrial Transformation and the Empowerment Journey of Cytiva
Yi Zhu:Gene Therapy Technology Lead, Cytiva China
13:45-14:00 Extreme Manufacturing and Its Applications in Nucleotide Monomer Synthesis
Fang Zhao:Research Professor, East China Normal University
14:00-14:15 CMC Research of Nucleic Acid Therapeutics: Manufacturing and Quality Control from Starting Phosphoramidite Monomers to Drug Substances
Qing Li:CEO, Tianjin Pharma, Desano Group
14:15-14:30 Development of Nucleic Acid Drugs Based on Novel Nucleic Acid Modifications and Exploration of Ophthalmic Applications
Chuan Zhang:Founder & CEO, Rehydration Therapeutics
14:30-14:45 Analytical Characterization Challenges and Solutions for Nucleic Acid Medicines
Lei Ma:Biopharmaceutical Application Specialist, Waters